+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

All Ages
All Genders
ID05230017

Chinese Antiphospholipid Syndrome Cohort Collaborative Networks Study to Track Persistent Antiphospholipid Antibodies and Clinical Outcomes

Led by Peking Union Medical College Hospital · Updated on 2024-07-30

2000

Participants Needed

18

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This research focuses on Antiphospholipid Syndrome APS, an autoimmune disorder that can cause blood clots and pregnancy problems in people with persistent antiphospholipid antibodies aPLs. The study aims to create the first multicenter group of patients with persistent aPLs in China to better understand the full range of symptoms and risks, including those beyond the standard thrombotic and pregnancy issues. It will also evaluate the use of extra-standard antibody tests in this population. The project will enroll about 2000 patients from six centers across China, led by the Peking Union Medical College Hospital. Patients will have their antibodies tested and confirmed by a central laboratory. Every six months for up to three years, researchers will collect detailed information on thrombotic events, pregnancy complications, and other clinical signs related to aPLs to gain a comprehensive view of the condition. Participants will be followed regularly for up to three years, with visits every six months to track clinical events and antibody profiles. The study will record vascular thrombosis, pregnancy-related issues, and additional clinical symptoms outside the usual criteria. This ongoing monitoring will help assess the risks and prognosis for people with persistent aPLs and inform future testing standards in China.

CONDITIONS

Brief Title

Chinese AntiphosPholipid Syndrome cohorT cOllaborative NEtworks

Research Team

J

Jiuliang Zhao, M.D.

Y

Yangzhong Zhou, M.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here